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We investigated the potential diﬀerential eﬀects of antiretroviral therapies on unbalanced chemokine homeostasis and on
the progression of atherosclerosis in HIV-infected patients. A two-year prospective study was performed in 67 consecutive
HIV-infected patients initiating antiretroviral therapy with abacavir/lamivudine or tenofovir/emtricitabine. Circulating levels
of inﬂammatory biomarkers, progression of subclinical atherosclerosis and expression levels of selected chemokines genes in
circulating leukocytes were assessed. Control subjects showed signiﬁcantly lower plasma concentrations of CRP, tPA, IL-6, and
MCP-1 than HIV-infected patients at a baseline. After two years of followup, the observed decreases in plasma inﬂammatory
biomarker levels were only signiﬁcant for MCP-1, tPA, and IL-6. The decrease in plasma MCP-1 concentration was associated with
the progression of atherosclerosis, and this eﬀect was negligible only in patients receiving TDF-based therapy. Multivariate analysis
conﬁrmedthattreatmentwithTDFwaspositivelyandsigniﬁcantlyassociatedwithahigherlikelihoodofsubclinicalatherosclerosis
progression. However, the expression levels of selected genes in blood cells only showed associations with the viral load and total
and HDL-cholesterol levels. Current antiretroviral treatments may partially attenuate the inﬂuence of HIV infection on certain
inﬂammatory pathways, though patients receiving TDF therapy must be carefully monitored with respect to the presence and/or
progression of atherosclerosis.
1.Introduction
Coronary artery disease (CAD) and the accumulation of
classical cardiovascular risk factors are becoming increas-
ingly common in human immunodeﬁciency virus (HIV)-
infected patients [1]. However, these cardiovascular risk
factors alone do not explain the increased incidence of CAD
in these patients; classical risk scores typically underestimate
the risk of coronary events in these patients, and there is a
signiﬁcant nonconcordance with subclinical atherosclerosis
in HIV-infected subjects [2, 3]. Antiretroviral treatment-
induced dyslipidemia has previously been considered suf-
ﬁcient to induce atherosclerosis in these patients; however,
recent evidence suggests that both inﬂammation and speciﬁc
responses to some antiretroviral treatment regimens play
important roles in the development of the disease [4]. In
particular, the identiﬁcation of inﬂammatory biomarkers
and the assessment of direct HIV-related damage to the
arterial wall are currently subjects of intense research [5–7].
Clinical studies show that HIV infection, HIV treatment
regimens and inﬂammation are independent factors asso-
ciated with the development of atherosclerotic lesions [8].
It is also well documented that plasma concentrations of
cytokines,includinginterleukin(IL)-6,tumornecrosisfactor
alpha (TNF-α), monocyte chemotactic protein 1 (MCP-
1/CCL2),andIL-18,arehigherinHIV-infectedpatientsthan2 Mediators of Inﬂammation
in uninfected individuals; furthermore, these diﬀerences
persist even in patients with well-controlled viral disease
[9–12]. Considering both inﬂammation and lipid-related
risk factors, we previously assessed the relationship between
plasma concentrations of high-density lipoproteins (HDL)
a n dH I Vv i r a ll o a d[ 13]. Our results indicated that HDL
particles modulate not only reverse cholesterol transport but
also the inﬂammatory response [14, 15]. Moreover, at least
in animal models, the anti-inﬂammatory action of HDL
in the development of atherosclerosis seems to be more
relevant than the actual enrichment of cholesterol [16]. The
potential diﬀerential eﬀects of antiretroviral therapies on
unbalanced chemokine homeostasis and on the progression
of atherosclerosis have not yet been investigated.
2.MaterialsandMethods
2.1. Study Participants. We recruited patients from among
the participants of an observational nonrandomized lon-
gitudinal project assessing atherosclerosis in HIV-infected
patients [17]; all subjects agreed to participate in the present
study and provided informed consent. The initial time-point
of this study was the commencement of therapy includ-
ing either abacavir lamivudine (ABC-3TC) or tenofovir
emtricitabine (TDF-FTC). Candidates for inclusion were
antiretroviral na¨ ıve patients, and patients previously exposed
to antiretroviral treatment who had discontinued treatment
foratleast6months.Nopatientwasbeingtreatedwithlipid-
lowering drugs at the commencement of the study, but 5
patients were treated with ﬂuvastatin (80mg/day) during the
followup in ABC-3TC group and 3 in TDF-FTC group. For
the purpose of this study, only patients who remained on
the same antiretroviral treatment regimen during followup
were included in the analysis. The study was approved by the
Ethics Committee of the Hospital Universitari Sant Joan.
After informed consent forms were read and signed
by the patients, complete physical examinations were per-
formed, a fasting venous blood sample was drawn for
analyses, and baseline scans of the carotid arteries were
obtained. Data relating to smoking habits, alcohol consump-
tion, opportunistic infections, hepatitis C virus (HCV) coin-
fection, the period of time since the original diagnosis, and
speciﬁc therapies received by patients were collected. Lab-
oratory analyses included lipid proﬁles, blood glucose con-
centration evaluations, assessments of inﬂammatory marker
expression, plasma HIV-1 RNA level analysis, and blood
CD4+ T cell counts. Serum HDL-cholesterol concentration
was measured using a homogeneous assay based on the
synthetic polymer/detergent method, version 3 (Beckman-
Coulter, Fullerton, CA, USA), and LDL-cholesterol con-
centration was calculated using the Friedewald formula.
Inﬂammatorymarkerlevelsandlipidproﬁleswerecompared
with those obtained from sex and age-matched unrelated
and uninfected control subjects who were recruited as
described previously [18]. After two-year followup, a second
ultrasonographic examination of the carotid arteries was
performed. In addition, with the rationale that whole blood
could reﬂect molecular changes that take place in response to
diﬀerent antiretroviral therapy in other key organs/tissues, a
blood sample was obtained from each patient to evaluate the
CCL2, CCR5, CCR2, and CXCR-4 gene expression proﬁles
of circulating leukocytes and to assess treatment-related
diﬀerences as described below.
2.2. Measurement of Inﬂammatory Biomarkers. EDTA-
plasma was used for all of the measurements described. The
concentration of C-reactive protein (CRP) was measured
using a particle-enhanced turbidimetric immunoassay
(Quantex hs-CRP kit, Biokit, Barcelona, Spain) with a
sensitivity of 0.10mg/L. Soluble CD40 ligand (sCD40L),
IL-6, IL-8, MCP-1, soluble platelet selectin (P-selectin), and
tissue plasminogen activator (t-PA) levels were measured
using a Human Cardiovascular FlowCytomix Multiplex kit
(Bender MedSystems, Vienna, Austria).
2.3. Standardized Ultrasound Protocol. The carotid ultra-
sound measurement was performed essentially as described
by Polak et al. [19] with the addition of some previously
published modiﬁcations [20]. We used a GE Logiq 700
Ultrasound Machine with a 7- to 10-MHz ultrasound probe.
We identiﬁed and digitally recorded the far wall of the
common carotid artery (1cm proximal to the bifurcation),
the carotid bulb (in the bifurcation), and the internal carotid
artery (1cm distal to the bifurcation). All of the intimamedia
thickness (IMT) measurements were performed at prede-
ﬁned points using AnaliSYS image processing software (Soft
ImagingSystem,M¨ unster,Germany).IMTmeasurementson
eacharterialsegmentwereaveragedandusedinthestatistical
analyses as a combined IMT. To assess reproducibility of
measurements, the images of 20 randomly selected patients
were remeasured applying the same protocol. The intraclass
correlation coeﬃcient between the 2 sets of measurements
was 0.91, and the absolute diﬀerence in IMT was 0.007mm
(0.018).
2.4. Gene Expression Analysis. Three millilitres of blood were
collected from subjects and directly deposited into TEMPUS
blood RNA tubes (Applied Biosystems, Foster City, CA,
USA). Total RNA was then isolated from these samples
usinganABIPRISM6100NucleicAcidPrepStation(Applied
Biosystems). All TaqMan primers and probes were obtained
from Assays-on-Demand (Applied Biosystems) and were
used in a Micro Fluidic Card on a 7900HT Real-Time
PCR system (Applied Biosystems). Micro Fluidic Cards were
analysed with RQ documents and the RQ Manager Software.
The expression levels of the CCL2, CCR5, CCR2, and CXCR-
4 genes were normalized to the expression of a designated
endogenous control gene (GAPDH). Gene expression levels
were calculated using the comparative threshold cycle (Ct)
method.
2.5. Statistical Analysis. Analysis was performed using SPSS,
version 19.0 (SPSS Inc., Chicago, IL). All data are pre-
sented as mean ± SD, except where otherwise stated.
The Kolmogorov-Smirnov test was used to check whether
data were normally distributed. Diﬀerences in baselineMediators of Inﬂammation 3
characteristics between the two treatment groups were
assessed through the χ2 and Mann-Whitney U test for
categorical and continuous variables, respectively. To asses
whether changes in biomarkers levels were signiﬁcantly
diﬀerentfrombaselineineachtreatmentgroup,andwhether
those changes were signiﬁcantly diﬀerent between both
treatment groups, we used linear mixed models including
the interaction between treatment group and study period
as categorical. Univariate and multivariate analyses were
performed, with adjustment for confounding factors such
as sex, age, BMI, third antiretroviral drug, coinfection
with HCV and lipid-lowering therapy. We calculated the
diﬀerence in the combined IMT scores between the two
examinations (delta IMT). For the assessment of factors
that aﬀect changes in IMT, the patients were divided into
two groups, the progressors and nonprogressors,b a s e do n
the mean annual increment of IMT (delta IMT, mm/year).
Progressors were deﬁned as those with a mean annual delta
IMT ≥0.015mm/year, whereas non-progressors as those with
a delta IMT <0.015mm/year according to the result of the
meta-analysis which estimated the mean annual change in
IMT among control groups from 13 published randomized
placebo-controlled studies [21]. Patients were also grouped
according to tertiles for HDL-cholesterol, total cholesterol,
LDL-cholesterol, and triglycerides. Stepwise regression anal-
ysis was performed to identify prognostic factors for the
delta IMT score. In the stepwise analysis method, variables
were introduced one-by-one into the model; only variables
that were found to be statistically signiﬁcant remained in the
model.
3. Results
3.1. General Characteristics of HIV-Infected Patients. Of the
67 Caucasian subjects who met selection criteria, 35 (52.2%)
initiated TDF-FTC and 32 (47.8%) ABC-3TC. The third
component of the regimen was an nonnucleoside reverse
transcriptase inhibitor (NNRTI) in 77% and 64% and a
protease inhibitor (PI) in 33% and 46% patients treated with
TDF-FTC and ABC-3TC, respectively. Thirty-eight patients
(56.7%) were antiretroviral treatment na¨ ıve patients and
29 (43.3%) were patients reinitiating antiretroviral therapy
after treatment interruption for at least 6 months. Of the
67 patients initially selected, data obtained from 13 patients
were excluded due to cardiovascular disease events (n = 2),
unstable followups (n = 8) or poor quality of the recorded
images (n = 3). No signiﬁcant diﬀerences were observed
between antiretroviral treatment groups for the variables
considered here. The main clinically relevant characteristics
of the patients included in the study are summarized in
Table 1. The mean time from diagnosis was 7.24±0.36 years,
and 38 (56.7%) patients were coinfected with HCV. These
patients were either current or past intravenous drug users
(59%) or became infected as a result of sexual intercourse.
The baseline examination revealed that most patients
were heavy smokers, were relatively young, were not
signiﬁcantly obese, and had normal blood pressure val-
ues. The mean plasma lipid and glucose concentrations
were determined to be within laboratory reference ranges.
Demographic-, HIV-, or cardiovascular risk-related baseline
characteristics were not signiﬁcantly diﬀerent between pa-
tients on TDF-FTC- or ABC-3TC-based regimens (Table 1).
However, control subjects showed signiﬁcantly lower plasma
concentrations of CRP (P<0.001), tPA (P<0.001), IL-6
(P = 0.04), and MCP-1 (P = 0.03) than HIV-infected pa-
tients at the baseline time point (Table 1).
3.2. Variables Related to the Progression of Atherosclerosis.
There was a signiﬁcant mean annual increase (0.045mm)
in the IMT between the baseline measurements [0.77
(0.01)mm] and the followup values [0.85 (0.01)]. Baseline
values were not signiﬁcantly inﬂuenced by the inﬂammatory
markers or the lipid proﬁle. We used the delta IMT
to segregate the patients into progressors [delta IMT =
0.22 (0.01)mm] and nonprogressors [delta IMT = −0.05
(0.02)mm] so as to identify variables that may inﬂuence the
course of atherosclerosis (Table 2). None of the classical car-
diovascular disease risk factors were signiﬁcantly associated
with the course of IMT. When patients were stratiﬁed by
circulating levels of total, LDL-, and HDL-cholesterol, the
proportion of patients with high total and LDL-cholesterol
concentrations was higher among the progressors in both
groupsofpatients,butthediﬀerencesdidnotreachstatistical
signiﬁcance. Only the use of TDF was signiﬁcantly associated
with the progression of subclinical atherosclerosis (Table 2).
The TDF group showed a higher proportion of progressors
(61%) with respect to ABC group (33%; P = 0.003).
When we applied multivariate stepwise regression analysis
to identify variables that could be associated with the
progression of atherosclerosis in HIV-infected patients, the
results conﬁrmed that TDF-based treatment was positively
and signiﬁcantly associated with a higher likelihood of
subclinical atherosclerosis progression (OR = 7.1, P = 0.002,
95% CI: 2–24).
3.3. Variables Related to Inﬂammatory Biomarkers. In HIV-
infected patients, but not in control subjects, the plasma
concentrationofHDL-cholesterolwasfoundtobenegatively
correlated with the expression levels of tPA (ρ = −0.3, P =
0.001), MCP-1 (ρ = −0.25; P = 0.002), P-selectin (ρ =
0.17, P = 0.018), IL-6 (ρ = −0.18, P = 0.016), and IL-
8( ρ = −0.17, P = 0.013). No correlation was found with
other lipid-related parameters, and no signiﬁcant diﬀerences
in the concentrations of inﬂammatory biomarkers related to
the antiretroviral treatment group were observed at baseline.
In the second evaluation, the mean CD4+ T-cell count
was signiﬁcantly increased [462.9 (27.1) versus 523.6 (27.8)
in cell/μL, P<0.001], 89% of patients exhibited a HIV
viral load <200 copies/mL, and total plasma and LDL-
cholesterol levels were found to be signiﬁcantly decreased
in both groups of antiretroviral treatment. Interestingly,
after two years of followup, the observed decreases in the
plasma concentrations of inﬂammatory biomarkers were
only signiﬁcant for MCP-1 (P<0.001), tPA (P<0.001) and
IL-6 (P = 0.01) (Figure 1). Accordingly, although plasma
MCP-1 levels were decreased in all patients (Figure 2(a)),4 Mediators of Inﬂammation
Table 1: Characteristics of the control group (n = 151) and HIV-infected patients (n = 67) at baseline and at follow-up by treatment group.
Characteristics Control group
HIV-infected patients
ABC-3TC (n = 35) TDF-FTC (n = 32)
Baseline Followup Baseline Followup
Gender, male (%) 135 (67) 24 (68) NA 20 (62) NA
Age, years 39.1 (0.4) 38.9 (0.6) NA 38.3 (0.6) NA
BMI, kg/m2 26.2 (0.2) 23.31 (0.2) 23.52 (0.4) 23.21 (0.2) 23.82 (0.3)
Systolic blood pressure, mm Hg 119.14 (1.7) 118.04 (1.4) 120.46 (1.5) 118.45 (1.5) 121.01 (1.5)
Diastolic blood pressure, mm Hg 77.36 (1.2) 75.96 (1.1) 78.35 (1.9) 76.26 (1.4) 78.01 (0.97)
Smoking, n (%) 90 (39.7)a 23 (66) 21 (62) 20 (62) 19 (59)
Total WBC count, cells x 109/L NA 4.27 (1.6) 4.73 (2.1) 4.50 (1.9) 4.83 (2.0)
CD4+ Tc e l lc o u n t ,c e l l s / μL NA 458.97 (20.0)b 526.33 (24.8) 469.87 (20.2)b 520.25 (26.8)
Total cholesterol, mmol/L 5.02 (0.3) 5.06 (0.1)b 4.90 (0.1) 4.99 (0.1)b 4.80 (0.1)
HDL cholesterol, mmol/L 1.47 (0.1)a 1.17 (0.04) 1.19 (0.04) 1.18 (0.04) 1.19 (0.03)
LDL cholesterol, mmol/L 2.78 (0.3) 2.82 (0.1)b 2.68 (0.1) 2.88 (0.1)b 2.58 (0.1)
Triglycerides, mmol/L 1.1 (0.3) 2.50 (0.2) 2.53 (0.2) 2.49 (0.2) 2.59 (0.2)
Glucose, mmol/L 4.91 (0.4) 5.42 (0.1) 5.40 (0.2) 5.42 (0.2) 5.35 (0.1)
CRP, mg/L 0.83 (0.1)a 4.67 (3.4) 4.81 (3.9) 4.85 (3.2) 4.76 (4.2)
MCP-1, pg/mL 427.9 (149.7)a 830.8 (193.3)b 555.1 (96.2) 846.4 (198.1) 826.3 (113.9)
sCD40L, ng/mL 2.03 (0.2) 1.64 (0.4) 1.56 (0.3) 1.60 (0.5) 1.71 (0.7)
tPA, ng/mL 5.63 (0.5)a 9.71 (0.86)b 6.60 (0.64) 9.45 (0.79)b 6.10 (0.64)
IL-6, pg/mL 3.29 (0.8)a 7.19 (1.3)b 6.19 (1.3) 7.11 (1.5)b 6.30 (1.1)
IL-8, pg/mL 14.88 (6.1) 36.38 (5.2) 32.92 (8.1) 36.99 (7.3) 34.01 (7.9)
P-Selectin, pg/mL 185.23 (50.4) 205.19 (88.8) 199.05 (70.9) 211.11 (79.8) 200.35 (72.6)
Data are the mean (SEM) unless otherwise indicated. aP<0.05 with respect to baseline values of all HIV-infected patients; bP<0.05 with respect to follow-
up values. BMI, body-mass index; NA, not applicable; WBC: white blood cells.
Table 2: Comparison of baseline values in groups segregated by the
course of IMT.
Characteristics Nonprogressors
(n = 21)
Progressors
(n = 46)
Gender, male (%) 14 (67) 30 (65)
Age, years 40.1 (1.1) 39.9 (1.1)
BMI, kg/m2 22.9 (0.2) 23.1 (0.2)
Systolic blood pressure, mm Hg 119.9 (2.7) 115.9 (1.9)
Diastolic blood pressure, mm Hg 79.6 (1.4) 77.3 (1.3)
Smoking, n (%) 13 (62) 30 (65)
TDF-FTC-based therapy, n (%) 7 (33) 28 (61)∗
CD4+ Tc e l lc o u n t ,c e l l s / μL 463.2 (46.1) 469.9 (19.3)
Total cholesterol, mmol/L 4.79 (0.3) 5.02 (0.4)
HDL cholesterol, mmol/L 1.18 (0.2) 1.17 (0.1)
LDL cholesterol, mmol/L 2.66 (0.3) 2.79 (0.4)
Triglycerides, mmol/L 2.48 (0.3) 2.51 (0.3)
Glucose, mmol/L 5.40 (0.4) 5.41 (0.4)
Delta IMT, mm −0.05 (0.01) 0.22 (0.01)∗
Data are the mean (SEM) unless otherwise indicated. aP<0.05 with respect
to nonprogressors BMI, body-mass index.
this decrease was not signiﬁcant among progressors [845.6
(205.3) pg/mL at baseline versus 710.9 (115.6) pg/mL at
followup; P = 0.079]. Furthermore, as shown in Figure 2(b),
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Figure 1: Changes in plasma concentrations of inﬂammatory
markers after two years of followup. The observed decreases in
plasma concentrations of inﬂammatory biomarkers (expressed as
percentages) were only signiﬁcant for MCP-1, tPA, and IL-6.
the decrease in MCP-1 levels were signiﬁcantly smaller in
patientsinitiatingTDF-FTC[846.4(198.1)pg/mLatbaseline
versus 826.3 (113.9) pg/mL at followup; P = 0.2] compared
with those starting ABC-3TC [830.8 (193.3) pg/mL at
baseline versus 555.1 (96.2) pg/mL at followup; P = 0.01].
3.4. Gene Expression Analysis in Circulating Leukocytes. To
test if these results could be explained by changes in blood
cell gene expression patterns, we measured CCL2, CCR5,
CCR2, and CXCR-4 gene expression levels. We found noMediators of Inﬂammation 5
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Figure 2: Changes in plasma concentration of MCP-1 after two years of followup in HIV-infected patients. A decrease in plasma MCP-
1 concentration was observed in all HIV-infected patients, though it was more prominent and signiﬁcant in those who did not display
progression of atherosclerosis (a). Stratiﬁcation according to antiretroviral treatment strategy (b) revealed that the decrease in plasma MCP-
1 concentration was not signiﬁcant in patients receiving TDF-FTC.
diﬀerences between the antiretroviral treatment groups.
HIV-related characteristics, such as HCV coinfection and
the time and route of infection, were also unrelated to the
gene expression patterns. However, we observed signiﬁcantly
lower CCL2, CCR5,a n dCCR2 gene expression levels in
patients exhibiting measurably better virological control
(Figure 3(a)). Surprisingly, we also found that CCL2 and
CCR2 gene expression levels were lower in patients with the
highest cholesterol levels (Figure 3(b)). In addition, lower
CCL2 gene expression levels were observed in patients with
the highest plasma concentrations of LDL-cholesterol (P =
0.023) and plasma triglycerides (P = 0.04). In contrast, lipid
parameters were not correlated with the expression levels
of CCR5 or CXCR-4. We further assessed the role of lipid
variables in the level of CCL2 gene expression, and we found
a negative correlation with total cholesterol concentrations
in patients receiving ABC-3TC (ρ = −0.5, P = 0.004).
In contrast, plasma HDL-cholesterol concentrations were
positively correlated with MCP-1 gene expression levels (ρ
= 0.6, P = 0.006) in patients receiving TDF-FTC. Finally,
nonprogressors with the highest plasma HDL-cholesterol
concentrationspresentedasigniﬁcantdecreaseinCCR5gene
expression levels (P = 0.04) (Figure 3(c)).
4. Discussion
New therapies have dramatically decreased the mortality of
patients infected with HIV, though recent ﬁndings suggest
that several treatment-associated alterations may play a role
in future morbidity and life expectancy. Among these alter-
ations, the presence and/or progression of atherosclerosis
with subsequent risk of myocardial infarction is a matter
of concern [1–8]. Predisposing factors, such as lipoprotein
disturbances and altered circulating cytokine proﬁles and
monocytes subsets, have been previously demonstrated to
o c c u ri nr e s p o n s et os p e c i ﬁ ct r e a t m e n t sa n di nr e s p o n s et o
HIV infection itself [9–12]. Our data indicate that, regard-
less of the treatments administered, eﬀects are observed
for some cytokines but not for others. Infected patients
exhibited increased plasma concentrations of CRP, tPA,
IL-6, and MCP-1, but other cytokines (i.e., P-selectin,
sCD40L, IL-8) seemed to be unresponsive to HIV infection.
The mechanisms that trigger the selective production of
cytokines, and consequently inﬂuence the overall inﬂam-
matory response, remain undeﬁned, though our ﬁndings
suggest that these may be associated, at least partially, with
the well-documented anti-inﬂammatory role of HDL [15].
In this sense, the patients involved in this study showed low
HDL-cholesterol levels relative to controls, and signiﬁcant
correlations between plasma levels of HDL-cholesterol and
most of the measured cytokines were observed, suggesting
that HDL particles may lose their anti-inﬂammatory proper-
ties in HIV infection. During metabolic/inﬂammatory stress,
HDL may become dysfunctional, exhibiting proinﬂamma-
tory and consequently proatherogenic eﬀects. Altered HDL
cholesterol concentrations are common in HIV-infected
patients and are usually attributed to the eﬀects of both
antiretroviral drugs and HIV infection itself [22, 23]. It
is not fully understood whether HDL particle distribution6 Mediators of Inﬂammation
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Figure 3:ChangesintheexpressionlevelsofCCL2,CCR2,andCCR5genes.Theexpressionlevelsofselectedcytokine-relatedgenesinblood
cells of HIV-infected patients in relation to HIV viral load (a), total cholesterol levels (b), and HDL-cholesterol (HDL-c) concentration (c).
may add relevant information to the function of HDL in
the absence or presence of HIV treatment, and whether
such eﬀect adds further signiﬁcance to the accelerated
atherosclerosis observed in these patients. However, our
results are concordant with previous ﬁndings that higher
plasma MCP-1 concentration is associated with higher
rates of atherosclerosis [20]. The lack of correlation with
plasma concentrations of CRP and sCD40L observed in this
study may be explained by the complementary disturbances
in endothelial cell and liver functions that are frequently
observed in HIV-infected patients [24–26].
In the present study, we also found that continuous
antiretroviral therapy may substantially reduce the plasma
concentrations of some cytokines, thus attenuating the levels
of surrogate cardiovascular risk markers. The observed eﬀect
on plasma MCP-1, IL-6, and tPA concentrations was high,
but the eﬀect on other cytokines tested was negligible. After
two years of followup, the decrease in plasma tPA and IL-6
concentrations was found to be unrelated to the treatment
regimen given, and the eﬀects on both were quantitatively
moderate. However, plasma MCP-1 concentrations only
decreased in those treated patients who did not receive
TDF. This is concordant with experimental studies showing
that TDF may increase the production of MCP-1 via an
NF-κB-related pathway [27]. Such eﬀects, which we have
conﬁrmed clinically, should be considered deleterious. AsMediators of Inﬂammation 7
shown by our results, the reduction in plasma MCP-1 levels
is greater in those subjects considered to be nonprogressors
in comparison to subjects in which atherosclerotic lesions
progressed. Moreover, multivariate analysis conﬁrmed that
TDF treatment was positively and signiﬁcantly associated
with a higher likelihood of atherosclerosis progression. Such
arelationshipisplausibleaccordingtopreviousﬁndings.The
absence of MCP-1 or its receptor, CCR2, in susceptible mice
protects against the development of atherosclerotic lesions,
a condition in which macrophage recruitment and lipid
overload play crucial roles. It has been also demonstrated
that the MCP-1/CCR2 signalling pathway may represent a
common pathway for many proatherogenic factors and that
this pathway plays a central role in monocyte recruitment,
lesion formation, and vascular repair [28, 29]. In HIV-
infected patients, genetic variations in the CCL2/CCR2 path-
way have been associated with survival, and polymorphisms
that increase the expression of CCL2 have been repeatedly
associated with the presence of subclinical atherosclerosis
[30–32].
When we assessed the expression levels of relevant genes
in blood cells, we found that a detectable viral load is a
determinant of the relative expression levels of the CCL2,
CCR2, and CCR5 genes. Furthermore, this modulation was
not related to the treatment regimen group investigated
in our study. This result is in accordance with the well-
established ﬁnding that viral proteins such as the transac-
tivator of transcription (Tat) protein may increase the in
vitro expression of CCR5 and CXCR-4, the main coreceptors
for HIV [33]. It is particularly noteworthy that CCR5 is
an emerging therapeutic target; critically, blocking agents
targeting this receptor may inhibit not only HIV replication
but also atherosclerotic progression, a pleiotropic eﬀect that
should be thoroughly considered [34]. It is also of note
that in our patients the relative decrease in the CCR5 gene
expressionlevelswasassociatedwithhigherHDL-cholesterol
levels,aneﬀectthatwasobservedonlyamongnonprogressors.
There was also a concomitant association between decreased
CCL2 and CCR2 gene expression levels and higher total
cholesterol levels; this eﬀect deserves further research and
is likely related to the total burden of oxidized LDL as
previously described [23].
Finally, it is important to note that changes that occur in
monocytes and macrophages during HIV infection are also
likely to impact on atherogenic processes [35], and we have
not assessed them in the present study. The CD14+/CD16+
“proinﬂammatory” monocyte subpopulation is preferen-
tially susceptible to HIV infection and may play a critical role
in the pathogenesis of HIV-related cardiovascular disease.
Moreover, both CCR5 and CCR2 expression levels correlate
signiﬁcantly with CD14+/CD16+ monocyte subset [36], and
metabolic abnormalities such as dyslipidemia and insulin
resistance, have been also reported to promote an inﬂamma-
tory phenotype in circulating monocytes [37].
A limitation to this study is that the number of patients
included was relatively low and eight of them were treated
with statin during the followup. These aspects limit the
validity of the conclusions, which should be conﬁrmed in
controlled larger populations. Another drawback was the
nonrandomized assignment of therapy groups, which could
have inﬂuenced the signiﬁcant diﬀerences observed between
groups.
In conclusion, TDF-based therapy had no beneﬁcial
eﬀect on circulating MCP-1 concentration and was signif-
icantly associated with a higher likelihood of subclinical
atherosclerosis. Our data reinforce the notion that HIV
infection modulates factors that strongly inﬂuence certain
inﬂammatorypathways[38–40]andreﬂectthecomplexityof
phenomena accompanying antiretroviral therapy initiation
in viremic patients, which might suggest a closer monitoring
with respect to cardiovascular disease risk during the initial
phases of treatment.
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